Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants-Reference-Cited by-同舟云学术

Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants

Published:2021-08-10 Issue:6 Volume:14 Page:2420-2430
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Scheible Holger¹^ORCID,Dyroff Martin²,Seithel‐Keuth Annick¹,Harrison‐Moench Eleanor¹,Mammasse Nadra³,Port Andreas¹,Bachmann Angelika¹,Dong Jennifer²,Lier Jan Jaap⁴,Tracewell William⁵,Mitchell David⁵

Affiliation:

1. The healthcare business of Merck KGaA Darmstadt Germany

2. EMD Serono Billerica Massachusetts USA

3. Cytel Inc Paris France

4. PRA Health Sciences Groningen The Netherlands

5. Nuventra Inc Exton Pennsylvania USA

Funder

Merck KGaA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13108

Reference28 articles.

1. Multiple Sclerosis International Federation. Atlas of MS 2013.2013.

2. The Treatment experience, burden, and unmet needs (TRIBUNE) study – measuring the socioeconomic consequences of Multiple Sclerosis

3. The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature

4. New insights into the burden and costs of multiple sclerosis in Europe

5. Treatment of multiple sclerosis with interferon beta : an appraisal of cost-effectiveness and quality of life

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bruton Tyrosine Kinase Inhibition Decreases Inflammation and Differentially Impacts Phagocytosis and Cellular Metabolism in Mouse- and Human-derived Myeloid Cells;ImmunoHorizons;2024-09-01

2. Use of Structural Alerts for Reactive Metabolites in the Application SpotRM;Chemical Research in Toxicology;2024-08-01

3. Predicting the Intravenous Pharmacokinetics of Covalent Drugs in Animals and Humans;Journal of Medicinal Chemistry;2024-07-17

4. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases;Autoimmunity Reviews;2024-05

5. Academic foreign compound metabolism – ‘ quo vadis ’?;Xenobiotica;2024-04-24